MOLN
Molecular Partners AG
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
4.51
▲ 0.28 (6.62%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
4.38
Prev close
4.23
Day high
4.40
Day low
4.38
Volume
483
Market cap
$165.05M
P/E (TTM)
—
52W range
3.53 – 5.36
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+4.51%
+5.9%
1M
+10.83%
+7.1%
3M
+15.79%
+12.7%
6M
-12.00%
-23.1%
YTD
+0.94%
-11.3%
1Y
+24.29%
+4.3%
3Y
-27.51%
-101.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$165.05M
Enterprise value$89.62M
Revenue (TTM)—
Gross profit$-36.66M
EBITDA$-51.89M
Net income$-58.02M
EPS (TTM)$-1.94
Free cash flow$-25.20M
Total cash$78.77M
Total debt$3.34M
Book value / share$2.25
Shares outstanding37.51M
Float19.92M
Short % of float0.01%
Dividend yield—
Beta (5Y)0.68
Short interest
Shares short
1.39K
Prior 1.75K
Change vs prior
-20.9%
Shorts covering
% of float
0.01%
Normal
% of shares out
0.00%
Against total outstanding
Days to cover
0.3
Liquid
Float
19.92M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E—
Forward P/E-16.81
PEG ratio—
Price / sales—
Price / book1.95
EV / revenue—
EV / EBITDA-1.73
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-59.01%
Return on assets-28.82%
Debt / equity4.89
Current ratio9.43
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $4.97M | $7.04M | $189.56M | -100.0% |
| Operating revenue | $0 | $4.97M | $7.04M | $189.56M | -100.0% |
| Research & development | $40.19M | $48.60M | $48.78M | $50.75M | -17.3% |
| Selling, general & admin | $14.87M | $17.16M | $19.00M | $21.82M | -13.4% |
| Total operating expense | $55.44M | $66.19M | $68.15M | $72.94M | -16.2% |
| Operating income | -$55.44M | -$61.22M | -$61.11M | $116.61M | +9.4% |
| Net interest income | $1.49M | $3.35M | $4.23M | $523.00K | -55.5% |
| Pre-tax income | -$61.65M | -$54.04M | -$61.98M | $117.85M | -14.1% |
| Tax provision | $2.00K | $2.00K | $0 | $0 | 0.0% |
| Net income | -$61.65M | -$54.04M | -$61.98M | $117.85M | -14.1% |
| Net income to common | -$61.65M | -$54.04M | -$61.98M | $117.85M | -14.1% |
| Basic EPS | -1.65 | -1.59 | -1.89 | 3.63 | -3.8% |
| Diluted EPS | -1.65 | -1.59 | -1.89 | 3.54 | -3.8% |
| EBIT | -$61.63M | -$54.02M | -$61.95M | $118.46M | -14.1% |
| EBITDA | -$59.49M | -$51.65M | -$59.53M | $120.85M | -15.2% |
| Basic shares | 37.27M | 34.03M | 32.77M | 32.47M | +9.5% |
| Diluted shares | 37.27M | 34.03M | 32.77M | 33.27M | +9.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $82.65M | $63.87M | $67.31M | $87.95M | +29.4% |
| Cash & short-term investments | $93.06M | $149.44M | $186.89M | $249.14M | -37.7% |
| Accounts receivable | $253.00K | $286.00K | $295.00K | $521.00K | -11.5% |
| Total current assets | $96.88M | $154.28M | $192.46M | $254.75M | -37.2% |
| Property, plant & equipment | $5.23M | $4.20M | $5.68M | $7.24M | +24.6% |
| Goodwill & intangibles | $2.00K | $49.00K | $212.00K | $271.00K | -95.9% |
| Total assets | $102.11M | $158.53M | $198.35M | $262.26M | -35.6% |
| Total current liabilities | $11.03M | $10.79M | $14.42M | $17.25M | +2.2% |
| Total debt | $3.64M | $2.44M | $3.65M | $4.85M | +49.1% |
| Total liabilities | $21.77M | $16.89M | $21.92M | $27.09M | +28.9% |
| Retained earnings | -$311.75M | -$246.29M | -$191.75M | -$127.78M | -26.6% |
| Shareholder equity | $80.33M | $141.64M | $176.43M | $235.17M | -43.3% |
| Working capital | $85.85M | $143.50M | $178.04M | $237.50M | -40.2% |
| Net tangible assets | $80.33M | $141.59M | $176.22M | $234.90M | -43.3% |
| Shares issued | 40.37M | 40.36M | 36.35M | 36.04M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$61.65M | -$54.04M | -$61.98M | $117.85M | — | -14.1% |
| Depreciation & amortisation | $2.14M | $2.37M | $2.42M | $2.39M | — | -9.5% |
| Stock-based compensation | $4.42M | $4.11M | $5.21M | $5.09M | — | +7.6% |
| Change in working capital | $1.21M | -$3.80M | -$6.01M | -$6.01M | — | +131.9% |
| Operating cash flow | -$51.26M | -$59.25M | -$59.01M | $118.57M | — | +13.5% |
| Capital expenditure | -$714.00K | -$723.00K | -$808.00K | -$1.42M | — | +1.2% |
| Investing cash flow | $72.55M | $40.49M | $44.64M | -$101.12M | — | +79.2% |
| Share buybacks | — | $0 | $0 | -$631.00K | $0 | — |
| Financing cash flow | -$1.15M | $14.43M | -$1.17M | -$1.57M | — | -108.0% |
| Free cash flow | -$51.97M | -$59.97M | -$59.81M | $117.15M | — | +13.3% |
| End cash position | $82.65M | $63.87M | $67.31M | $87.95M | — | +29.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $9.45M | $9.24M | $8.33M | $10.71M | $11.92M | +2.2% |
| Selling, general & admin | $4.00M | $3.06M | $3.60M | $3.99M | $4.22M | +30.8% |
| Total operating expense | $13.44M | $12.67M | $11.93M | $14.70M | $16.14M | +6.1% |
| Operating income | -$13.44M | -$12.67M | -$11.93M | -$14.70M | -$16.14M | -6.1% |
| Net interest income | $165.00K | $224.00K | $359.00K | $413.00K | $493.00K | -26.3% |
| Pre-tax income | -$13.14M | -$12.64M | -$11.84M | -$20.40M | -$16.77M | -3.9% |
| Tax provision | $0 | $4.00K | $0 | $0 | -$2.00K | -100.0% |
| Net income | -$13.14M | -$12.65M | -$11.84M | -$20.40M | -$16.77M | -3.9% |
| Net income to common | -$13.14M | -$12.65M | -$11.84M | -$20.40M | -$16.77M | -3.9% |
| Basic EPS | -0.35 | — | -0.33 | -0.56 | -0.45 | — |
| Diluted EPS | -0.35 | — | -0.33 | -0.56 | -0.45 | — |
| EBIT | -$13.14M | -$12.64M | -$11.83M | -$20.39M | -$16.77M | -3.9% |
| EBITDA | -$12.64M | -$12.13M | -$11.31M | -$19.84M | -$16.21M | -4.2% |
| Basic shares | 37.50M | — | 37.40M | 37.39M | 36.87M | — |
| Diluted shares | 37.50M | — | 37.40M | 37.39M | 36.87M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $64.25M | $82.65M | $82.36M | $81.97M | $81.37M | -22.3% |
| Cash & short-term investments | $78.77M | $93.06M | $104.52M | $114.49M | $130.91M | -15.4% |
| Accounts receivable | $2.31M | $253.00K | $2.10M | $3.60M | $3.98M | +814.2% |
| Total current assets | $82.93M | $96.88M | $108.96M | $120.57M | $136.95M | -14.4% |
| Property, plant & equipment | $4.73M | $5.23M | $3.19M | $3.68M | $4.12M | -9.6% |
| Goodwill & intangibles | $1.00K | $2.00K | $5.00K | $10.00K | $24.00K | -50.0% |
| Total assets | $87.66M | $102.11M | $112.15M | $124.25M | $141.10M | -14.2% |
| Total current liabilities | $8.80M | $11.03M | $11.74M | $12.90M | $8.96M | -20.2% |
| Total debt | $3.34M | $3.64M | $1.53M | $1.84M | $2.14M | -8.2% |
| Total liabilities | $19.21M | $21.77M | $16.62M | $17.59M | $12.90M | -11.8% |
| Retained earnings | -$324.63M | -$311.75M | -$295.59M | -$283.38M | -$260.88M | -4.1% |
| Shareholder equity | $68.45M | $80.33M | $95.53M | $106.66M | $128.19M | -14.8% |
| Working capital | $74.13M | $85.85M | $97.22M | $107.67M | $127.99M | -13.7% |
| Net tangible assets | $68.45M | $80.33M | $95.52M | $106.65M | $128.17M | -14.8% |
| Shares issued | 40.37M | 40.37M | 40.37M | 40.37M | 40.37M | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$13.14M | -$12.65M | -$11.84M | -$20.40M | -$16.77M | — | -3.9% |
| Depreciation & amortisation | $501.00K | $512.00K | $527.00K | $553.00K | $552.00K | — | -2.1% |
| Stock-based compensation | $936.00K | $973.00K | $1.08M | $1.23M | $1.14M | — | -3.8% |
| Change in working capital | -$2.50M | -$224.00K | $408.00K | $3.81M | -$2.78M | — | -1,017.0% |
| Operating cash flow | -$14.24M | -$11.15M | -$9.93M | -$13.10M | -$17.08M | — | -27.7% |
| Capital expenditure | — | -$139.00K | -$31.00K | -$96.00K | -$448.00K | -$137.00K | — |
| Investing cash flow | -$3.93M | $11.95M | $10.66M | $14.97M | $34.96M | — | -132.9% |
| Financing cash flow | -$292.00K | -$300.00K | -$304.00K | -$243.00K | -$302.00K | — | +2.7% |
| Free cash flow | -$14.24M | -$11.29M | -$9.96M | -$13.20M | -$17.53M | — | -26.2% |
| End cash position | $64.25M | $82.65M | $82.36M | $81.97M | $81.37M | — | -22.3% |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Mar 2026 | -0.33 | — | — |
| Dec 2025 | -0.30 | -0.36 | -22.0% |
| Sep 2025 | -0.37 | -0.33 | +10.8% |
| Jun 2025 | -0.44 | -0.56 | -27.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.35 | 2 | $0 | 0.0% |
| Next quarter | -0.36 | 2 | $0 | 0.0% |
| Current year | -1.16 | 3 | $5.58M | 0.0% |
| Next year | -0.21 | 3 | $30.69M | +450.0% |
Analyst targets & ownership
Mean target$11.23
High target$17.12
Low target$3.78
Implied upside148.96%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 4
Hold1
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions9.58%
Institutions holding6
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 16, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 27, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Dec 8, 25 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Sep 3, 25 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Mar 11, 25 | LifeSci Capital | INITIATED | — | Outperform |
| Dec 5, 23 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Aug 29, 22 | SVB Leerink | DOWNGRADE | Outperform | Market Perform |
| May 25, 22 | Credit Suisse | UPGRADE | Underperform | Neutral |
| Apr 27, 22 | SVB Leerink | MAINTAINED | — | Outperform |
| Jan 14, 22 | SVB Leerink | MAINTAINED | — | Outperform |
| Aug 27, 21 | SVB Leerink | MAINTAINED | — | Outperform |
Moving averages & technicals
SMA 10
4.23
+6.59% from price
SMA 20
4.12
+6.70% from price
SMA 50
4.02
+9.51% from price
SMA 100
4.06
+11.08% from price
SMA 200
4.23
+3.95% from price
EMA 12
4.22
+6.81% from price
EMA 26
4.14
+9.06% from price
EMA 50
4.09
+10.35% from price
RSI (14)
64.9
Neutral
MACD (12,26,9)
0.09
Hist 0.02
ATR (14)
0.06
1.36% of price
Realised vol 30D
38.5%
Annualised
Bollinger upper
4.41
20, 2σ
Bollinger lower
3.84
20, 2σ
50 / 200 cross
Death
4.02 vs 4.23
Trend bias
Above 200
+3.95%
Risk profile
Beta vs SPY
0.17
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
38.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-27.6%
Peak to trough
Max drawdown 5Y
-89.6%
Peak to trough
ATR 14
0.06
1.36% of price
Beta (reported)
0.68
5Y monthly, from filing
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-07-20
Corporate Changes & Voting Matters
6-K · 2026-07-07
Corporate Changes & Voting Matters
6-K · 2026-07-02
Offering Registrations
S-8 · 2026-06-24
Corporate Changes & Voting Matters
6-K · 2026-06-01
Corporate Changes & Voting Matters
6-K · 2026-05-12
Corporate Changes & Voting Matters
6-K · 2026-05-01
Corporate Changes & Voting Matters
6-K · 2026-04-14
Headlines
Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy
MT Newswires · 38d ago
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
GlobeNewswire · 38d ago
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
GlobeNewswire · 39d ago
Molecular Partners Makes Progress on Radiotherapy Cancer Candidates
MT Newswires · 48d ago
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
GlobeNewswire · 48d ago
Molecular Partners Doses First Patients in Lung Cancer Trial
MT Newswires · 52d ago
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
GlobeNewswire · 52d ago
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
GlobeNewswire · 84d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.